ALPS Medical Breakthroughs ETF (AMEX:SBIO) broke out with the outbreak of a round of biopharmaceutical stocks from the beginning of 2015 to the present, and is currently one of the best performing crude drug ETFs this year.
SBIO fund situation:
The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the Poliwogg Medical Breakthroughs IndexSM. The fund employs a “passive management” – or indexing – investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology and pharmaceutical companies that have one or more drugs in either Phase II or Phase III U.S. Food and Drug Administration clinical trials. It is non-diversified.